HDAC6 and Parkinson disease: These results suggest that SIRT2-mediated α-tubulin deacetylation plays essential roles in α-syn-mediated PD pathogenesis and that targeting SIRT2 inhibition rather than HDAC6 inhibition is a potential therapeutic strategy for α-syn-related PD.